大麻使用障碍与择期非心脏大手术后围术期并发症风险
该回顾性匹配队列研究基于美国国家住院样本2016–2019年数据,纳入18–65岁接受大型择期住院非心脏手术的成人,将6211例大麻使用障碍患者与6211例无该障碍患者进行倾向评分1:1匹配。作者建议将术前大麻使用障碍筛查纳入围术期风险分层。
要点
- 大麻使用障碍与大型择期非心脏手术后围术期并发症和死亡复合结局风险轻度升高相关。
- 匹配队列中暴露组复合结局发生率为7.73%,非暴露组为6.57%。
- 建议将术前大麻使用障碍筛查作为围术期风险分层的组成部分。
核心结论
- 作者认为研究结果支持将术前大麻使用障碍筛查纳入围术期风险分层,但尚需进一步研究量化不同使用途径和剂量对围术期的影响。
研究设计与样本
- 回顾性、基于人群的倾向评分匹配队列研究,数据来自美国国家住院样本(National Inpatient Sample)。
- 纳入2016年1月至2019年12月期间18–65岁接受大型择期住院非心脏手术的成人,手术类型包括胆囊切除术、结肠切除术、腹股沟疝修补术、股疝修补术、乳房切除术、肿物切除术、髋关节置换术、膝关节置换术、子宫切除术、脊柱融合术和椎间盘切除术。
- 暴露定义依据ICD-10中特定大麻使用障碍诊断编码,经1:1倾向评分匹配后共6211例暴露患者与6211例非暴露患者进入分析;暴露组中位年龄53岁(IQR 44–59),男性3498例(56.32%)。
- 匹配协变量包括患者合并症、社会人口学因素和手术类型,匹配后组间均衡。
- 数据分析时间为2022年2月至8月。
主要发现
- 主要复合结局为院内死亡及7项主要围术期并发症(心肌缺血、急性肾损伤、卒中、呼吸衰竭、静脉血栓栓塞、医院获得性感染和手术操作相关并发症),依据ICD-10出院诊断编码判定。
- 复合结局在暴露组发生480例(7.73%),在非暴露组发生408例(6.57%)。
关键数值与推荐
- 暴露定义:存在ICD-10中特定大麻使用障碍诊断编码。
- 主要复合结局:院内死亡及7项主要围术期并发症(心肌缺血、急性肾损伤、卒中、呼吸衰竭、静脉血栓栓塞、医院获得性感染、手术操作相关并发症)。
- 匹配方法:倾向评分1:1匹配,协变量包括合并症、社会人口学因素和手术类型。
临床怎么用
- 对拟行大型择期非心脏手术的成人,可考虑术前筛查大麻使用障碍,作为围术期风险分层的组成部分。
- 对合并大麻使用障碍的患者,术前应提高对围术期并发症和死亡风险的警惕,但具体戒烟(大麻)建议尚待进一步研究。
- 临床解读该关联时需注意其为观察性研究结果,不能直接推断因果关系。
局限性
- 原文未明确列出局限性,但研究为回顾性数据库分析,暴露和结局均基于ICD-10编码,可能存在编码偏倚。
- 原文指出尚需进一步研究量化不同使用途径和剂量对围术期的影响,并据此制定术前大麻戒断建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cannabis use is growing in the US and is increasingly perceived as harmless. However, the perioperative impact of cannabis use remains uncertain. OBJECTIVE: To assess whether cannabis use disorder is associated with increased morbidity and mortality after major elective, inpatient, noncardiac surgery. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based, matched cohort study used data from the National Inpatient Sample for adult patients aged 18 to 65 years who underwent major elective inpatient surgery (including cholecystectomy, colectomy, inguinal hernia repair, femoral hernia repair, mastectomy, lumpectomy, hip arthroplasty, knee arthroplasty, hysterectomy, spinal fusion, and vertebral discectomy) from January 2016 to December 2019. Data were analyzed from February to August 2022. EXPOSURE: Cannabis use disorder, as defined by the presence of specific International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnostic codes. MAIN OUTCOME AND MEASURES: The primary composite outcome was in-hospital mortality and 7 major perioperative complications (myocardial ischemia, acute kidney injury, stroke, respiratory failure, venous thromboembolism, hospital-acquired infection, and surgical procedure-related complications) based on ICD-10 discharge diagnosis codes. Propensity score matching was performed to create a 1:1 matched cohort that was well balanced with respect to covariates, which included patient comorbidities, sociodemographic factors, and procedure type. RESULTS: Among 12 422 hospitalizations, a cohort of 6211 patients with cannabis use disorder (median age, 53 years [IQR, 44-59 years]; 3498 [56.32%] male) were matched with 6211 patients without cannabis use disorder for analysis. Cannabis use disorder was associated with an increased risk of perioperative morbidity and mortality compared with hospitalizations without cannabis use disorder in adjusted analysis (adjusted odds ratio, 1.19; 95% CI, 1.04-1.37; P = .01). The outcome occurred more frequently in the group with cannabis use disorder (480 [7.73%]) compared with the unexposed group (408 [6.57%]). CONCLUSIONS AND RELEVANCE: In this cohort study, cannabis use disorder was associated with a modest increased risk of perioperative morbidity and mortality after major elective, inpatient, noncardiac surgery. In the context of increasing cannabis use rates, our findings support preoperative screening for cannabis use disorder as a component of perioperative risk stratification. However, further research is needed to quantify the perioperative impact of cannabis use by route and dosage and to inform recommendations for preoperative cannabis cessation.
引用
- Potnuru PP, Jonna S, Williams GW, et al. Cannabis Use Disorder and Perioperative Complications. JAMA Surg. 2023. PMID: 37405729. doi:10.1001/jamasurg.2023.2403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。